This content is machine translated Acute lymphoblastic leukemias in children and adolescents Progress through better risk stratification Acute lymphoblastic leukemia is the most common childhood cancer. It is treated in a risk-adapted manner and is curable in the majority of cases. New innovative drugs such as immunotherapies…
View Post 10 min This content is machine translated Options in the relapse therapy of multiple myeloma. What comes after the first line? Factors such as pretreatment, age, patient performance, and comorbidities determine relapse therapy in multiple myeloma. Triple combinations with a proteasome inhibitor and/or an IMID are standard. Antibody therapies also play…
View Post 4 min This content is machine translated Childhood cancer Progress made in recent years does not reach everyone Early death after childhood cancer diagnosis remains a challenge. Infants, ethnic minorities, and the socioeconomically worse off are at higher risk for early death. The reasons for this need to…
View Post 7 min This content is machine translated Therapy for initial diagnosis of multiple myeloma Treatment protocols in the age of modern substances We are in the era of new efficient compounds against multiple myeloma. Nevertheless, high-dose chemotherapy followed by autologous stem cell transplantation remains an essential part of the first-line treatment of…
View Post 8 min This content is machine translated Multiple Myeloma Pathogenesis, clinic, diagnostics In multiple myeloma, the clinic leading to the diagnosis is derived from the end-organ damage. The diagnostic criteria were last updated in 2014. With well-established and widely available diagnostics, the…
View Post 5 min This content is machine translated EHA Congress in Madrid Earlier response does not translate into higher overall survival in CML Overall survival of patients with chronic myeloid leukemia cannot be altered by optimizations of imatinib therapy. This is despite the fact that earlier evaluations were able to demonstrate an influence…
View Post 5 min This content is machine translated ICML 2017 in Lugano Long-term data are positive At the ICML Congress, the audience gained insight into long-term data from two phase III trials in mantle cell lymphoma and chronic lymphocytic leukemia. The new results confirm the statements…
View Post 7 min This content is machine translated 10th Iron Academy, Zurich Iron deficiency in pregnancy and postpartum In Switzerland, about 32% of all pregnant women have an iron deficiency, which together with the resulting anemia can cause complications for mother and child. Oral and intravenous iron preparations…
View Post 3 min This content is machine translated Acute lymphoblastic leukemia Bispecific antibody in heavily pretreated patients. Blinatumomab forms a bridge between T cells and cancer cells. The bispecific antibody is proving its worth in a new phase III trial. It has been approved in Switzerland for…
View Post 7 min This content is machine translated Treatment of hemophilia New techniques to extend the half-life Prophylactic treatment with factor concentrates is now standard in the treatment of patients with severe hemophilia A. Conventional factor VIII and factor IX concentrates have a relatively short half-life and…
View Post 5 min This content is machine translated ASH 2016 in San Diego Multiple Myeloma Review As every year, the ASH Congress took place in the busy pre-Christmas season. This time, experts from hematology and oncology met in San Diego. Multiple myeloma was again an important…
